-
公开(公告)号:US20050075364A1
公开(公告)日:2005-04-07
申请号:US10871931
申请日:2004-06-18
申请人: Kap-Sun Yeung , Michelle Farkas , John Kadow , Nicholas Meanwell , Malcolm Taylor , David Johnston , Thomas Coulter , J. J. Wright
发明人: Kap-Sun Yeung , Michelle Farkas , John Kadow , Nicholas Meanwell , Malcolm Taylor , David Johnston , Thomas Coulter , J. J. Wright
IPC分类号: A61K31/405 , A61K31/4745 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/502 , A61K31/517 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/14 , C07D471/02 , C07D471/04 , C07D487/04 , C07D491/04
CPC分类号: C07D413/14 , C07D401/12 , C07D401/14 , C07D403/12 , C07D471/04 , C07D491/04
摘要: This invention provides compounds of Formula I, including pharmaceutically accceptable salts thereof, having drug and bio-affecting properties, their pharmaceutical compositions and method of use. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. The compounds of Formula I have the formula wherein: Z is Q is selected from the group consisting of m is 2; A is selected from the group consisting of cinnolinyl, napthyridinyl, quinoxalinyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, quinazolinyl, azabenzofuryl, and phthalazinyl each of which may be optionally substituted with one or two groups independently selected from methyl, methoxy, hydroxy, amino and halogen; and —W— is
-
公开(公告)号:US08211896B2
公开(公告)日:2012-07-03
申请号:US12896114
申请日:2010-10-01
申请人: Solomon Ungashe , Zheng Wei , J. J. Wright , Andrew Pennell
发明人: Solomon Ungashe , Zheng Wei , J. J. Wright , Andrew Pennell
IPC分类号: A61K31/4427 , A61K31/4523 , A61K31/501 , A61K31/506 , C07D213/34 , C07D239/26
CPC分类号: C07C311/29 , C07C311/21 , C07C311/46 , C07C317/14 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
摘要翻译: 提供了作为CCR9受体的有效拮抗剂的化合物,并且已经在用于CCR9的标志性疾病状态之一的炎症的动物试验中进一步证实了这些化合物。 化合物通常为芳基磺酰胺衍生物,并且可用于药物组合物,用于治疗CCR9介导的疾病的方法,以及用于鉴定CCR9拮抗剂的测定中的对照。
-
公开(公告)号:US07649011B2
公开(公告)日:2010-01-19
申请号:US10743281
申请日:2003-12-22
IPC分类号: A61K31/541 , A61K31/496 , C07D417/02
CPC分类号: C07D241/04 , C07C235/48 , C07C235/50 , C07D207/06 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/14 , C07D207/16 , C07D211/14 , C07D211/42 , C07D211/56 , C07D241/42 , C07D295/13 , C07D401/04 , C07D401/06 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14
摘要: Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.
摘要翻译: 公开了含有作为SDF-1或I-TAC趋化因子调节剂的有机化合物或其盐的药物组合物。 化合物和组合物可用于治疗癌症,特别是抑制癌细胞增殖,生长和转移。 还公开了使用本发明的化合物和药物组合物干扰SDF-1和/或I-TAC与CCXCKR2受体结合并治疗癌症的方法。
-
公开(公告)号:US20090163498A1
公开(公告)日:2009-06-25
申请号:US12137006
申请日:2008-06-11
申请人: Solomon Ungashe , J. J. Wright , Andrew Pennell , Zheng Wei , Anita Melikan
发明人: Solomon Ungashe , J. J. Wright , Andrew Pennell , Zheng Wei , Anita Melikan
IPC分类号: A61K31/5377 , C07D413/12 , A61K31/4439 , A61K31/4433 , C07D405/12
CPC分类号: C07D417/12 , A61K31/4409 , A61K31/443 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D213/26 , C07D213/50 , C07D213/52 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D239/26 , C07D241/12 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
-
公开(公告)号:US07420055B2
公开(公告)日:2008-09-02
申请号:US10846241
申请日:2004-05-13
申请人: Solomon Ungashe , J. J. Wright , Andrew Pennell , Zheng Wei , Anita Melikan
发明人: Solomon Ungashe , J. J. Wright , Andrew Pennell , Zheng Wei , Anita Melikan
IPC分类号: C07D413/10
CPC分类号: C07D417/12 , A61K31/4409 , A61K31/443 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D213/26 , C07D213/50 , C07D213/52 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D239/26 , C07D241/12 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
摘要翻译: 提供了作为CCR9受体的有效拮抗剂的化合物,并且已经在用于CCR9的标志性疾病状态之一的炎症的动物试验中进一步证实了这些化合物。 化合物通常为芳基磺酰胺衍生物,并且可用于药物组合物,用于治疗CCR9介导的疾病的方法,以及用于鉴定CCR9拮抗剂的测定中的对照。
-
6.
公开(公告)号:US07101894B2
公开(公告)日:2006-09-05
申请号:US10233326
申请日:2002-08-29
CPC分类号: C07D207/08 , A61K31/075 , A61K31/135 , A61K31/4709 , C07D207/27 , C07D211/14 , C07D211/26 , C07D231/12 , C07D241/04 , C07D295/088 , C07D295/096 , C07D295/135 , C07D295/155 , C07D453/04
摘要: Methods for treating CMV or a CMV-related disease are provided that use compounds having the formula: wherein Ar is a substituted or unsubstituted 5–14 membered heteroaryl group having from 1 to 5 heteroatoms as ring members; R1 is selected from the group consisting of substituted or unsubstituted aryl(C1–C4)alkyl, heteroaryl(C1–C4)alkyl, —C(O)R11, and —C(O)NR11R12, wherein each R11 and R12 independently is substituted or unsubstituted aryl, substituted or unsubstituted aryl(C1–C4)alkyl, substituted or unsubstituted (C4–C8)cycloalkyl(C1–C4)alkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl(C1–C4)alkyl and substituted or unsubstituted hetero(C4–C8)cycloalkyl(C1–C4)alkyl; R2 is H or (C1–C8)alkyl; and ZN is a substituted or unsubstituted hetero(C6–C10)bicycloalkyl group.
摘要翻译: 提供了使用具有下式的化合物治疗CMV或CMV相关疾病的方法:其中Ar是具有1至5个杂原子作为环成员的取代或未取代的5-14元杂芳基; R 1选自取代或未取代的芳基(C 1 -C 4 -C 4)烷基,杂芳基(C 1 H 4) -C(O)R 11和-C(O)NR 11 R 12 > 12,其中每个R 11和R 12独立地是取代或未取代的芳基,取代或未取代的芳基(C 1〜 C 1 -C 4烷基,取代或未取代的(C 1 -C 4 -C 8)环烷基(C 1 -C 4 - 取代或未取代的杂芳基,取代或未取代的杂芳基(C 1 -C 4 -C 4)烷基和取代或未取代的杂原子(C
-
公开(公告)号:US20100227902A1
公开(公告)日:2010-09-09
申请号:US12780390
申请日:2010-05-14
申请人: Solomon Ungashe , Zheng Wei , J. J. Wright , Andrew Pennell , Brett Permack , Thomas Schall
发明人: Solomon Ungashe , Zheng Wei , J. J. Wright , Andrew Pennell , Brett Permack , Thomas Schall
IPC分类号: A61K31/421 , C07C311/21 , A61K31/18 , C07D307/77 , A61K31/343 , C07D231/12 , C07D263/32 , A61K31/415 , A61P29/00 , C12N5/07
CPC分类号: C07D213/26 , A61K31/4245 , A61K31/433 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
摘要翻译: 提供了作为趋化因子受体的有效拮抗剂的化合物。 化合物通常为芳基磺酰胺衍生物,可用于药物组合物,治疗趋化因子受体介导的疾病的方法,以及用于鉴定趋化因子拮抗剂的测定中的对照。
-
公开(公告)号:US07227035B2
公开(公告)日:2007-06-05
申请号:US10848836
申请日:2004-05-19
申请人: Solomon Ungashe , Zheng Wei , J. J. Wright , Andrew Pennell , Brett Permack , Thomas Schall
发明人: Solomon Ungashe , Zheng Wei , J. J. Wright , Andrew Pennell , Brett Permack , Thomas Schall
IPC分类号: C07C303/00 , A61K31/33 , A61K31/397 , A61K31/55
CPC分类号: C07D213/26 , A61K31/18 , A61K31/195 , A61K31/397 , A61K31/4245 , A61K31/433 , A61K31/445 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K31/55 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
-
公开(公告)号:US20050137179A1
公开(公告)日:2005-06-23
申请号:US10848836
申请日:2004-05-19
申请人: Solomon Ungashe , Zheng Wei , J. J. Wright , Andrew Pennell , Brett Premack , Thomas Schall
发明人: Solomon Ungashe , Zheng Wei , J. J. Wright , Andrew Pennell , Brett Premack , Thomas Schall
IPC分类号: A61K31/18 , A61K31/195 , A61K31/397 , A61K31/445 , A61K31/55 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
CPC分类号: C07D213/26 , A61K31/18 , A61K31/195 , A61K31/397 , A61K31/4245 , A61K31/433 , A61K31/445 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K31/55 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
摘要翻译: 提供了作为趋化因子受体的有效拮抗剂的化合物。 化合物通常为芳基磺酰胺衍生物,可用于药物组合物,治疗趋化因子受体介导的疾病的方法,以及用于鉴定趋化因子拮抗剂的测定中的对照。
-
公开(公告)号:US06821998B2
公开(公告)日:2004-11-23
申请号:US10233336
申请日:2002-08-29
IPC分类号: A61K3140
CPC分类号: C07D207/08 , A61K31/075 , A61K31/135 , A61K31/4709 , C07D207/27 , C07D211/14 , C07D211/26 , C07D231/12 , C07D241/04 , C07D295/088 , C07D295/096 , C07D295/135 , C07D295/155 , C07D453/04
摘要: Methods for treating CMV and CMV-related diseases are provided that use compounds having the formula: wherein the subscripts m and n are each independently integers from 1 to 2; and the R groups are as defined in the specification.
摘要翻译: 提供用于治疗CMV和CMV相关疾病的方法,其使用具有下式的化合物:其中下标m和n各自独立地为1至2的整数; 并且R基团如说明书中所定义。
-
-
-
-
-
-
-
-
-